ArticleRadiation oncology (London, England)2025
The risk of symptomatic radiation pneumonitis in small cell lung cancer patients following sequential immunochemotherapy and radiotherapy: a multicenter retrospective cohort study.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveImmune checkpoint inhibitors plus thoracic radiotherapy (RT) may magnify the radiation pneumonitis (RP) risk. Data on the risk for symptomatic RP in small cell lung cancer (SCLC) patients following RT after induction immunochemotherapy using anti-programmed cell death protein-1 monoclonal antibody Serplulimab, cisplatin plus etoposide are limited.
methodsThis retrospective study included 443 SCLC patients from two hospitals who finished thoracic intensity-modulated radiation therapy or volumetric modulated arc therapy between April 1, 2022 and March 31, 2025. The primary endpoint was the incidence of grade 2 or worse (grade 2+) RP. Fine-Gray competing risks regression analyses were used to identify the potential risk factors of RP2+.
resultsThe follow-up duration was (15.8 ± 4.6) weeks since the end of RT. In detail, 87 (19.6%), 35 (7.9%), and 6 (1.4%) patients developed grade 2, grade 3, and grade 4 RP respectively. Six patients died from non-RP-related diseases were treated as competing events. On univariate analysis, male, pneumoconiosis, ECOG status, concurrent chemoradiotherapy (CCRT) were positively correlated with the incidence of RP2+, with subdistribution hazard ratio (SHR) and 95% confidence interval (CI) of 1.81 (1.29-2.55), 2.56 (1.35-4.87), 1.53 (1.17-1.99) and 2.15 (1.35-3.42), respectively (all P < 0.05), while VO
conclusionThe incidence of RP2 + following sequential immunochemotherapy and RT was positively associated with male and CCRT, but negatively correlated with VO CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.